Novo Nordisk Shareholders Approve Capital Strategy and Board Refresh

Novo Nordisk shareholders approved a 10% share buyback, a DKK 44.65M capital increase, and a DKK 11.70 dividend for 2025. The board added new members and settled a key patent dispute.

At its Annual General Meeting held on March 26, 2026, Novo Nordisk shareholders formally approved the company’s 2025 annual results and endorsed a suite of capital measures. The meeting also saw a refresh of the Board of Directors, a move CEO Lars Rebien Sørensen framed as part of a broader "year of profound change" for the pharmaceutical giant.

Strategic Financial Flexibility Granted

Shareholders greenlit a capital repurchase program authorizing the board to buy back up to 10% of the company’s share capital. This mandate is effective until the 2027 Annual General Meeting. In a separate move, approval was granted for a capital increase of a nominal DKK 44.65 million, with this authorization extending until April 2028. Management highlighted that these measures provide crucial financial flexibility to support the firm’s ongoing transformation.

Regarding shareholder returns, the total dividend for fiscal year 2025 was set at DKK 11.70 per share. An interim dividend of DKK 3.75 was already distributed in August 2025, with the remaining balance of DKK 7.95 per share scheduled for payment in March 2026.

Board Composition Evolves with New Appointments

Lars Rebien Sørensen was re-elected as Chair of the Board of Directors. The board welcomes three new members: Helena Saxon, Jan van de Winkel, and Ramona Sequeira. In a notable development, Poul Weihrauch, the Chief Executive Officer of Mars, was appointed as a board observer for the 2026/27 period, with a planned transition to full board membership starting in 2027.

Key Business Developments: Pricing and Partnerships

Beyond the AGM resolutions, two significant business updates are shaping Novo Nordisk’s trajectory. In early March 2026, the company reached a settlement with telehealth provider Hims & Hers in a patent dispute concerning compounded semaglutid. As part of the agreement, Hims & Hers will cease promotion of related copycat products and will instead offer FDA-approved medications, including Wegovy and Ozempic, through its platform.

On the pricing front, Novo Nordisk had already taken action in March 2025 by reducing the cost of Wegovy injections to $499 per month at pharmacies, down from a previous price point of $650. Furthermore, since January 2026, the lower-dose Wegovy pill (1.5 mg and 4 mg) has been available for $149 monthly through GoodRx.

Despite these strategic initiatives, the company’s share price currently trades approximately 29% below its level at the start of the year. Market participants are likely to await the next major strategic insights, which are expected at the Capital Markets Day scheduled for September 21, 2026.